NEW YORK – Metabolomics firm Nightingale Health said Tuesday that it has secured UK Conformity Assessed marking to offer its blood analysis technology for routine clinical use in the UK.
The Helsinki-based firm separately announced that Singapore's Health Sciences Authority has granted a second regulatory approval this year for the use of the company's blood testing technologies.
Nightingale said that it has already been working with universities in the UK on health initiatives such as the UK Biobank and using the company's technologies to profile their sample collections. The UKCA marking will help the company to expand use of those technologies into clinical settings.
"Nightingale Health's blood analysis technology demonstrates again its capabilities to become the new improved standard in routine blood testing for chronic diseases," Nightingale CEO Teemu Suna said in a statement. "By replacing the current methods of clinical chemistry, Nightingale Health's blood test can offer groundbreaking value in building more preventative and sustainable healthcare."
Suna added that the firm's tests also can be used to help clinicians assess a patient's risk of developing chronic diseases.
Nightingale said that it has established a lab in Porton Science Park in South Wiltshire, and the firm aims to offer local blood testing and expand its partnerships across the country's health system.
Meanwhile, Nightingale said that its most recent regulatory approval in Singapore will allow the use of its tests for the analysis of total fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, saturated fatty acids, omega-3 fatty acids, and omega-6 fatty acids. Earlier this year, Singapore regulators granted the company approval for the analysis of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, glucose, and creatinine.
Nightingale noted that it has been partnering since late 2023 with clinical diagnostics service provider Innoquest Diagnostics on the commercialization of Nightingale's blood analysis tools in Southeast Asia.
Nightingale said this spring that it was opening a US lab and it was partnering with Weill Cornell Medicine's clinical and research services. The firm and 23andMe also announced this summer a collaboration on the use of Nightingale's metabolomics panel on blood samples from up to 5,000 23andMe members.